Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease

International Clinical Psychopharmacology

Volumn 18, Issue 2, 2003, Pages 61-71

  Montgomery, Stuart A ^a,c   Thal, L J ^b   Amrein, R ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

Acetyl L carnitine; Alcar; Alzheimer's disease; Cognitive impairment; Dementia; Meta analysis; Placebo controlled

Indexed keywords

LEVACECARNINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; MATHEMATICAL COMPUTING; META ANALYSIS; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL;

ACETYLCARNITINE; AGED; ALZHEIMER DISEASE; COGNITION; HUMANS; NOOTROPIC AGENTS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 0037347231     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200303000-00001     Document Type: Article

References (77)

1. Agnoli (1994) Controlled clinical study with Acetyl-L-Carnitine versus Placebo in geriatric patients. Statistical Report, Study Protocol No: DRN-PS-84. On file Sigma-Tau.
2. Agnoli A (1985) Studio policentrico acetil-L-carnitina nei confronti di placebo in pazienti geriatrici. Risultati preliminari. In Abstracts of the IVth World Congress of Biological Psychiatry, 8-13 September 1985 Philadelphia, pp. 235.
3. Aureli T, Miccheli A, Ricciolini R, Di Cocco ME, Ramacci MT, Angelucci L, Ghirardi O, Conti F (1990). Aging brain: Effect of acetyl-L-carnitine treatment on rat brain energy and phospholipid metabolism. A study by 31P and 1H NMR spectroscopy. Brain Res 526: 108-112.
4. Barnes CA, Markowska AL, Ingram DK, Kametani H, Spangler EL, Lemken VJ, Olton DS (1990). Acetyl-L-carnitine 2: effects on learning and memory performance of aged rats in simple and complex mazes. Neurobiol Aging, 11: 499-506.
5. Bassi S, Ferrarese C, Finoia M (1988.) L-acetylcarnitine in Alzheimers disease and senile dementia Alzheimer type. In: Agnioli A, Cahn J, Lassen N, Mayeux R (editors): Senile dementia. Paris: J. Libbey; pp. 461-466.
6. Battistin L, Pizzolato G, Dam M, Ponza I, Perlotto N, Bergamo LC, et al. (1989). Effects of acetyl-L-carnitine (ALC) treatment in dementia: A multicentric, randomized, double-blind study. New Trends Clin Neuropharmacol 3: 131-132.
7. Bayer (1994). The Effect of Acetyl-L-Carnitine in Senile Dementia of the Alzheimer Type Clinical Report, Study Protocol No.: S104/1 CT4. On file Sigma-Tau.
8. Bellagamba (1991). Efficacy of Acetyl-L-Carnitine in Patients with Degenerative Dementia (SDAT)/Statistical Report, Study Protocol No.: DRN5-005. On file Sigma-Tau.
9. Bellagamba G, Postacchini D, Moretti V, Pennacchietti L. (1990). Acetyl-L-Carnitine Activity in Senile Dementia Alzheimer Type. Neurobiol Aging 11: 345-345 Abstract.
10. Berg L, McKeel DW, Miller JP, Baty J, Morris JC (1993). Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch Neurol 4: 349-358.
11. Bertolino A, Papagno G (1983). Attività della L-acetil carnitina nel deterioramento mentale. Clin Europ 2: 384-395.
12. Blessed G, Tomlinson BE, Roth M (1988). Blessed-Roth Dementia Scale (DS). Psychopharmacol Bull: 24: 705-708.
13. Boothby H, Mann AH, Barker A (1995). Factors determining interrater agreement with rating global change in dementia: The CIBIC-plus. Int J Geriat Psychiatry 10: 1037-1045.
14. Bravi D, Koch G, Calvani M, Bacchieri A, Pola P, Ni Bhuachalla S, Carta A (1994). In Society for Neurioscience, pp. 20 (1-2) abstract.
15. Brodaty H, Moore CM (1997). The clock drawing test for dementia of the Alzheimer's type: A comparison of three scoring methods in a memory disorders clinic. Int J Geriat Psychiatry 12: 619-627.
16. Burkart M, Heun R, Maier W, Benkert O (1998), [Dementia screening in routine clinical practice. A comparative analysis of MMSE, SIDAM and ADAS]. Nervenarzt 69: 983-990.
17. Burlina AP, Sershen H, Debler EA, Lajtha A (1989). Uptake of acetyl-L-carnitine in the brain. Neurochem. Res 14: 489-493.
18. Christensen H, Korten AE, Jorm AF, Henderson AS, Jacomb PA, Rodgers B, Mackinnon AJ (1997). Education and decline in cognitive performance: compensatory but not protective. Int J Geriat Psychiatry 12: 323-330.
19. Chu LW, Chiu KC, Hui SL, Yu GK, Tsui WJ, Lee PW (2000). The reliability and validity of the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) among the elderly Chinese in Hong Kong. Ann Acad Med Singapore 29: 474-485.
20. Cucinotta D, Passeri M, Ventura S, Ianuccelli M, Senin U, Bonati PA, Parnetti L (1988). Multicenter clinical placebo-controlled study with acetyl-L-carnitine (LAC) in the treatment of mildly demented elderly patients. Drug Devel Res 14: 213-216.
21. Demers L, Oremus M, Perrault A, Champoux N, Wolfson C (2000). Review of outcome measurement instruments in Alzheimer's disease drug trials: Psychometric properties of functional and quality of life scales. J Geriat Psychiatry Neurol 13: 170-180.
22. Egger M, Davey SmithG, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. Br Med J 315: 629-634.
23. Elwan O, Hashem S, Helmy AA, El Tamawy M, Naseer MA, Elwan F, et al. (1994). Cognitive deficits in ischemic strokes: Psychometric, electrophysiological and cranial tomographic assessment. J Neurol Sci 125: 168-174.
24. Erkinjuntti T, Hokkanen L, Sulkava R, Palo J (1988). The blessed dementia scale as a screening test for dementia. Int J Geriat Psychiatry 3: 267-273.
25. Fariello RG, Ferraro TN, Golden GT, DeMattei M (1988). Systemic acetyl-L-carnitine elevates nigral levels of glutathione and GABA. Life Sci 43: 289-292.
26. Folstein MF, Folstein SE, McHugh PR (1975). 'Mini mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 12: 189-198.
27. Frattola (1991). L-Acetyl Carnitine in Alzheimer Disease (A.D.) and Senile Dementia Alzheimer Type (S.D.A.T.). Statistical Report, Study Protocol No.: DRN2-005. On file Sigma-Tau.
28. Frattola L, Meregalli S, Bassi S, Finoia MG, Ianucelli M (1988). L-Acetyl-carnitine activity on SDAT patients. In: Cognition enhancers: from animal to man. II Int Symposium on preclinical strategies in psychopharmacology(Abstract) Paris.
29. Freidl W, Schmidt R, Stronegger WJ, Irmler A, Reinhart B, Koch M (1996). Mini mental state examination: influence of sociodemographic, environmental and behavioural factors and vascular risk factors. J Clin Epidemiol 49: 73-78.
30. Giuliani A, Calvani M, et al. (1990). In XVII Congress of Collegium Internationale Neuro-Psychopharmacologicum Kyoto, (abstract).
31. Glass GV (1976). Primary, secondary and meta-analysis of research. Rev Educat Res 5: 3-9.
32. Hedges LV, Olkin I (1985). Statistical Methods for Meta-Analysis. San Diego: Academic Press.
33. Herrmann (1988). Demonstration of the effects of Acetyl-L-Carnitine on impaired brain functions in geriatric outpatients. Clinical Report. Study Protocol No: KFB820-86. On file Sigma-Tau
34. Herrmann WM, Dietrich B, Hiersemenzel R (1990). Pharmacoelectroencephalographic and Clinical Effects of the Cholinergic Substance Acetyl-L-Carnitine in Patients with Organic Brain-Syndrome. Int J Clin Pharmacol Res 10: 81-84.
35. Ihl R, Grass-Kapanke B, Janner M, Weyer G (1999). Neuropsychometric tests in cross sectional and longitudinal studies - a regression analysis of ADAS - cog, SKT and MMSE. Pharmacopsychiatry 32: 248-254.
36. Jagger C, Clarke M, Anderson J, Battcock T (1992). Misclassification of dementia by the Mini-Mental State Examination - Are education and social class the only factors? Age Ageing 21: 404-411.
37. James (1992) The effect of Acetyl-L-Carnitine in senile dementia of Alzheimer type. Statistical Report, Study Protocol No.: S.104/1 CT1. On file Sigma-Tau.
38. Janiri L, Falcon M, Persico A, Tempesta E (1991). Activity of L-carnitine and L-acetylcarnitine on cholinoceptive neocortical neurons of the rat in vivo. J Neural Transmission General Sect 86: 135-146.
39. Jones RN, Gallo JJ (2001). Education bias in the mini-mental state examination. Int Psychogeriatrics 13: 299-310.
40. Kincaid MM, Harvey PD, Parrella M, White L, Putnam KM, Powchik P, et al. (1995). Validity and utility of the ADAS-L for measurement of cognitive and functional impairment in geriatric schizophrenic inpatients. J Neuropsychiatry Clin Neurosci 7: 76-81.
41. Launer LJ, Dinkgreve MAHM, Jonker C, Hooijer C, Lindeboom J (1993). Are age and education independent correlates of the Mini-Mental State Exam performance of community-dwelling elderly? J Gerontol 48: 271-277.
42. Lehninger A (1982.) Principles of biochemistry2. New York: Worth Publishers.
43. Leibovici D, Ritchie K, Ledesert B, Touchon J (1996). Does education level determine the course of cognitive decline? Age Ageing, 25: 392-397.
44. Light RJ, Pillemer DB (1984.) Summing Up: The Science of Reviewing Research. Cambridge, Mass: Havard University Press.
45. Livingston GA, Sax KB, McClenahan Z, Blumenthal E, Foley K, Willison J, Mann AH, James IM (1991). Acetyl-L-carnitine in dementia. Int J Geriat Psychiatry 6: 853-860.
46. Mantero (1991) Effects of Acetyl-L-Carnitine treatment in geriatric patients suffering from mental deterioration (double-blind placebo controlled study). Statistical Report, Study Protocol No.: DRN2-002. On file Sigma-Tau.
47. Mantero MA, Barbero M, Giannini R, Grosso VG, Tomasina C, Iannuccelli M (1989). Acetyl-L-carnitine as a therapeutic agent for mental deterioration in geriatric patients. (Double-blind placebo controlled study). New Trends Clin Neuropharmacol 3: 17-24.
48. Markowska AL, Ingram DK, Barnes CA, Spangler EL, Lemken VJ, Kametani H, Yee W, Olton DS (1990). Acetyl-L-carnitine 1: effects on mortality, pathology and sensory-motor performance in aging rats. Neurobiol Aging 11: 491-498.
49. Mohs RC, Cohen L (1988). Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull 24: 627-628.
50. Molarius A, Kuulasmaa K, Moltchanov V, Ferrario M (1998). Quality Assessment of Data on Marital Status and Educational Achievement in the WHO MONICA Project. WWW-publications from the WHO MONICA Project, http://www.ktl.fi/publications/monica/educ/educqa.htm.
51. Morris JC (1993). The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43: 2412-2414.
52. Mullin (1994). The Effect of Acetyl-L-Carnitine in Senile Dementia of the Alzheimer Type Clinical Report, Study Protocol No.: S104/1 CT3. On file Sigma-Tau.
53. Onofrj (1992) Evaluation of Efficacy of Chronic Administration (6 Months) of Acetyl-L-Carnitine in Patients Suffering from Senile Dementia Alzheimer Type (SDAT) and Alzheimer Disease (AD) Statistical Report, Study Protocol No.: ST20032189 (DRN4-021).
54. Ostrosky Solis F, Lopez Arango G, Ardila A (1999). Influences of age and education in the Mini Mental State Examination in a Spanish speaking population. Salud Mental 22: 20-26.
55. Pande S, Noel H, Murthy M (1986). Characteristics of, function of, and deficiency of carnitine acylcarnitine translocase. In: Borum P (editor): Clinical aspects of human carnitine deficiency. New York: Pergamon Press; pp. 166-180.
56. Passeri M, Cucinotta D, Bonafi PA, Iannuccelli M, Parnetti L, Senin U (1990). Acetyl-L-carnitine in the treatment of mildly demented elderly patients. Int J Clin Pharmacol Res 10: 75-79.
57. Petruzzella V, Baggetto LG, Penin F, Cafagna F, Ruggiero FM, Cantatore P, Gadaleta MN (1992). In vivo effect of acetyl-L-carnitine on succinate oxidation, adenine nucleotide pool and lipid composition of synaptic and non-synaptic mitochondria from cerebral hemispheres of senescent rats. Arch Gerontol Geriat 14: 131-144.
58. Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, McClure RJ (1995). Clinical and Neurochemical Effects of Acetyl-L-Carnitine in Alzheimers-Disease. Neurobiol Aging 16: 1-4.
59. Piovesan P, Pacifici L, Taglialatela G, Ramacci MT, Angelucci L (1994). Acetyl-L-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fibria-fornix transection. Brain Res 633: 77-82.
60. Rai (1989). Double-Blind Placebo-Controlled Parallel-Group Study of the Efficacy and Tolerability of Acetyl-L-Carnitine in Elderly Patients with Mild to Moderate Dementia of Alzheimer's Type. Clinical Report, Study Protocol No.: S104/1 CT2. On file Sigma-Tau.
61. Rai G, Wright G, et al. (1990). Double blind placebo controlled study of acetil-L-carnitine in patients with Alzheimer disease. Curr Med Res Opinion 10: 638-647.
62. Reisberg B, Ferris SH, de Leon MJ, Crook T (1982). The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 139: 1136-1139.
63. Ritchie K, Touchon J, Ledesert B, Leibovici D, Gorce AM (1997). Establishing the limits and characteristics of normal age-related cognitive decline. Rev Epidemiol Sante Publ 45: 373-381.
64. Rotmensch (1993) Efficacy and Safety of Acetyl-L-Carnitine versus Placebo upon Long-Term Treatment in Elderly Patients with Senile Dementia Alzheimer Type Clinical Report, Study Protocol No.: 09/0181-89. On file Sigma-Tau.
65. Sano M, Bell K, Cote L, Dooneief G, Lawton A, Legler L, Marder K, Naini A, Stern Y, Mayeux R (1992). Double-blind parallel design pilot study of acetyl levo-carnitine in patients with Alzheimer's disease. Arch Neurol 49: 1137-1141.
66. Spagnoli A, Lucca U, Menasce G, Bandera L, Cizza G, Forloni G, et al. (1991). Long-Term Acetyl-L-Carnitine Treatment in Alzheimers-Disease. Neurology 41: 1726-1732.
67. Taglialatela G, Navarra D, Cruciani R, Ramacci MT, Alema GS, Angelucci L (1994). Acetyl-L-carnitine treatment increase nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats. Exp Gerontol 29: 55-66.
68. Thal LJ, Calvani M, Amato A, Carta A (2000). A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. Neurology 55: 805-810.
69. Thal LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC, et al. (1996). A 1-Year Multicenter Placebo-Controlled Study of Acetyl-L-Carnitine in Patients With Alzheimers-Disease. Neurology 47: 705-711.
70. Tombaugh TN, McIntyre NJ (1992). The Mini-Mental State Examination: A comprehensive review. J Am Geriat Soc 40: 922-935.
71. Toth E, Harsing LG, Sershen H, Ramacci MT, Lajtha A (1993). Effect of Acetyl-L-Carnitine On Extracellular Amino-Acid Levels In vivo in Rat-Brain Regions. Neurochem Res 18: 573-578.
72. Uhlmann RF, Larson EB (1991). Effect of education on the mini-mental state examination as a screening test for dementia. J Am Geriat Soc 39: 876-880.
73. Vajdicková K, Kolibás E, Heretik A, Kosc M (1995). (Use of behavioral scales in the diagnosis of dementia in the aged). Ceská slovens psychiatrie 1: 7-14.
74. Villa RF, Gorini A, Zanada F, Benzi G (1986). Action of L-acetylcarnitine on different cerebral mitochondrial populations from hippocampus. Arch Int Pharmacodyn Therap 279: 195-211.
75. Villardita C, Lomeo C (1992). Alzheimer's disease: Correlational analysis of three screening tests and three behavioral scales. Acta Neurol Scand 86: 603-608.
76. White HL, Scates PW (1990). Acetyl-L-carnitine as a precursor of acetylcholine. Neurochem Res 15: 597-601.
77. Zhang M (1991). (Comparison of several screening instruments for dementia). Chung-Hua Shen Ching Ching Shen Ko Tsa Chih [Chin J Neurol Psychiatry] 4: 194-196, 251.